Lipocine Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lipocine stock.
View analyst ratings for Lipocine or view top-rated stocks.

Wall Street analysts have given Lipocine a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lipocine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Lipocine saw a decline in short interest in May. As of May 28th, there was short interest totaling 2,690,000 shares, a decline of 14.1% from the May 13th total of 3,130,000 shares. Based on an average daily volume of 2,130,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 3.1% of the company's shares are sold short.
View Lipocine's Short Interest.

Lipocine is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Lipocine.

Lipocine Inc. (NASDAQ:LPCN) posted its earnings results on Thursday, May, 6th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01.
View Lipocine's earnings history.

Lipocine's stock was trading at $0.4511 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LPCN shares have increased by 201.5% and is now trading at $1.36.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued 1-year target prices for Lipocine's stock. Their forecasts range from $2.50 to $3.00. On average, they anticipate Lipocine's share price to reach $2.75 in the next twelve months. This suggests a possible upside of 102.2% from the stock's current price.
View analysts' price targets for Lipocine or view top-rated stocks among Wall Street analysts.

Some companies that are related to Lipocine include Viking Therapeutics (VKTX), XBiotech (XBIT), Molecular Templates (MTEM), Landos Biopharma (LABP), Nabriva Therapeutics (NBRV), Greenwich LifeSciences (GLSI), Viracta Therapeutics (VIRX), TherapeuticsMD (TXMD), CytomX Therapeutics (CTMX), Gemini Therapeutics (GMTX), Avadel Pharmaceuticals (AVDL), Flexion Therapeutics (FLXN), BeyondSpring (BYSI), Akouos (AKUS) and MedAvail (MDVL).
View all of LPCN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Lipocine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ameriprise Financial Inc. (0.80%), Geode Capital Management LLC (0.68%), Mercer Global Advisors Inc. ADV (0.24%), Virtu Financial LLC (0.22%), Northern Trust Corp (0.17%) and GSA Capital Partners LLP (0.14%). Company insiders that own Lipocine stock include John W Higuchi, Mahesh V Patel and Morgan R Brown.
View institutional ownership trends for Lipocine.

LPCN stock was sold by a variety of institutional investors in the last quarter, including Mercer Global Advisors Inc. ADV, GSA Capital Partners LLP, Ameriprise Financial Inc., and Virtu Financial LLC. Company insiders that have sold Lipocine company stock in the last year include John W Higuchi, Mahesh V Patel, and Morgan R Brown.
View insider buying and selling activity for Lipocine or view top insider-selling stocks.

LPCN stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Price T Rowe Associates Inc. MD, Squarepoint Ops LLC, Cubist Systematic Strategies LLC, MML Investors Services LLC, XTX Topco Ltd, Jane Street Group LLC, and Northern Trust Corp. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi, and Mahesh V Patel.
View insider buying and selling activity for Lipocine or or view top insider-buying stocks.

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LPCN stock can currently be purchased for approximately $1.36.

Lipocine has a market capitalization of $120.08 million and generates $170,000.00 in revenue each year. The specialty pharmaceutical company earns $-20,960,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

Lipocine employs 13 workers across the globe.

The official website for Lipocine is www.lipocine.com.

Lipocine is headquartered at 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108.

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]